Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

ANTIGEN RECOGNITION IN AUTOIMMUNE ENCEPHALOMYELITIS AND THE POTENTIAL FOR PEPTIDE-MEDIATED IMMUNOTHERAPY CELL Wraith, D. C., Smilek, D. E., Mitchell, D. J., Steinman, L., McDevitt, H. O. 1989; 59 (2): 247-255

Abstract

Peptide binding and lymph node T cell activation studies have been used to characterize T cell recognition of an encephalitogenic T cell autoantigen from myelin basic protein in (PL/J x SJL)F1 mice. Amino acids that determine interactions with either the restriction element of the major histocompatibility complex (MHC) or the encephalitogenic T cell receptor are defined. This information enables the design of peptides that bind MHC yet do not cross-react with the autoantigen. A peptide analog of the encephalitogenic epitope is shown to be "heteroclitic" for MHC binding and activation of encephalitogenic T cells in vitro. This analog is not immunogenic for encephalitogenic T cells in vivo and is shown to inhibit disease that is induced by the autoantigen itself.

View details for Web of Science ID A1989AW74600006

View details for PubMedID 2478291